SCHEMBL5439596

SCHEMBL5439596

CCOC(=O)C(O)=Cc1ccnc(N(Cc2ccc(F)cc2C)C(=O)OC(C)(C)C)c1[N+](=O)[O-]

nearest known ligand 0.33

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.33
KDM5A P29375 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.30
CCNT1 O60563 1/20 0.30
CDK9 P50750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5439591 1.00 FBP1 (0.33) FBP1KDM5AKDM4CKDM5BALDH1A1
SCHEMBL5439602 1.00 FBP1 (0.33) FBP1KDM5AKDM4CKDM5BALDH1A1
Potassium Ion SCHEMBL2477023 0.92 FBP1 (0.33) FBP1MAPTCCNT1CDK9
SCHEMBL5435846 0.85 KDM4E (0.38) ALDH1A1
SCHEMBL5435852 0.85 KDM4E (0.38) ALDH1A1
SCHEMBL2473102 0.84 CCNT1 (0.35) KDM5AKDM4CKDM5BALDH1A1MAPT
SCHEMBL2475151 0.83 MAPT (0.30) MAPTCCNT1CDK9
Potassium Ion SCHEMBL2476667 0.79 KDM4E (0.37) ALDH1A1
SCHEMBL5437601 0.74 SMN1; SMN2 (0.39) KDM5AKDM4CKDM5BALDH1A1MAPT
SCHEMBL5437592 0.74 SMN1; SMN2 (0.39) KDM5AKDM4CKDM5BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1787991-B2 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 EP disclosed
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2018-05-31 US disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE PGA5, ATP6AP1, PPA1 FBP1 660/4885KDM5A 790/4885KDM4C 355/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 FBP1 660/4885KDM5A 790/4885KDM4C 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.